Valvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or both

Basit Öğe Kaydı
dc.authoridOzben, Serkan/0000-0002-2227-4104
dc.authoridOzben, Beste/0000-0002-3484-6392
dc.authorwosidÖztürk, Oya/GWM-4050-2022
dc.authorwosidOzben, Serkan/X-6407-2019
dc.contributor.authorOzer, Feriha
dc.contributor.authorTiras, Raziye
dc.contributor.authorCetin, Sibel
dc.contributor.authorOzturk, Oya
dc.contributor.authorAydemir, Tuba
dc.contributor.authorOzben, Serkan
dc.contributor.authorMeral, Hasan
dc.date.accessioned2024-08-04T20:31:05Z
dc.date.available2024-08-04T20:31:05Z
dc.date.issued2009
dc.departmentİnönü Üniversitesien_US
dc.description.abstractCardiac valvulopathy has been reported ill patients with Parkinson's disease treated with pergolide. The aim of this Study was to clarify the frequency and severity of valvular heart disease (VHD) in patients treated with pergolide, levodopa or both. We evaluated VHD by transthoracic echocardiography in 25 patients who were taking pergolide, 29 patients taking levodopa and 20 patients taking both levodopa and pergolide. All groups were compared with two separate age-matched control groups. There was no increase ill the frequency of any type of echocardiographically-significant Valvulopathy in the periodic groups. significant aortic regurgitation was found in 8% of the patients in the pergolide group and ill 37.9% of the patients in the levodopa group. There was no correlation between VHD and pergolide dose. cumulative dose or duration of therapy. The mean pergolide dose was 2.6 +/- 1.4 mg/day in the pergolide monotherapy group. We did not find any unequivocal evidence that pergolide causes significant valvular regurgitation. However. the mean pergolide dosage ill our study was lower than ill previous studies. (c) 2008 Elsevier Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.jocn.2008.02.005
dc.identifier.endpage87en_US
dc.identifier.issn0967-5868
dc.identifier.issue1en_US
dc.identifier.pmid19014887en_US
dc.identifier.scopus2-s2.0-57049117301en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage83en_US
dc.identifier.urihttps://doi.org/10.1016/j.jocn.2008.02.005
dc.identifier.urihttps://hdl.handle.net/11616/94706
dc.identifier.volume16en_US
dc.identifier.wosWOS:000262348500014en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Sci Ltden_US
dc.relation.ispartofJournal of Clinical Neuroscienceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectLevodopaen_US
dc.subjectParkinson's diseaseen_US
dc.subjectPergolideen_US
dc.subjectValvulopathyen_US
dc.titleValvular heart disease in patients with Parkinson's disease treated with pergolide, levodopa or bothen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu